{"id":35380,"date":"2026-06-08T17:45:00","date_gmt":"2026-06-08T12:15:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35380"},"modified":"2026-06-09T10:14:36","modified_gmt":"2026-06-09T04:44:36","slug":"rise-of-oral-serds","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds","title":{"rendered":"Oral SERDs Defy the Odds Amid a History of Pipeline Setbacks"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a32727197ced\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a32727197ced\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds\/#A_Decade_of_Heartbreak_The_Failures_That_Shaped_the_Field\" >A Decade of Heartbreak: The Failures That Shaped the Field<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds\/#The_Survivors_in_the_Graveyard\" >The Survivors in the Graveyard<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds\/#A_Pipeline_Brimming_with_Promise\" >A Pipeline Brimming with Promise<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds\/#The_Road_Ahead_Whats_Next_for_Oral_SERDs\" >The Road Ahead: What&#8217;s Next for Oral SERDs?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>HR+\/HER2- breast cancer continues to represent a major target indication for SERDs, with approximately 481,000 cases reported in 2024 in the 7MM.&nbsp;<\/em><\/li>\n\n\n\n<li><em>High-profile failures from Sanofi (amcenestrant) and a long list of early-stage candidates such as GDC-029, AZD9496, GDC-0927, ZnC5, LSZ-102, brinalestrant (GDC-0810), and rintodestrant forced the field to reckon with hard lessons.<\/em><\/li>\n\n\n\n<li><em>The turning point came with elacestrant (ORSERDU), the first-ever approved oral SERD in January 2023, followed by Eli Lilly&#8217;s imlunestrant (INLURIYO) in September 2025.<\/em><\/li>\n\n\n\n<li><em>The oral SERD pipeline is among the most active in oncology today, with agents such as camizestrant (AstraZeneca), Giredestrant (Roche\/Genentech), OP-1250 (Olema Oncology), SIM0270 (Simcere), AND019 (Kind Pharmaceuticals), and others in various stages of development.<\/em><\/li>\n<\/ul>\n\n\n\n<p>In the high-stakes world of breast cancer drug development, few drug classes have generated as much excitement, and as much heartbreak, as oral selective estrogen receptor degraders, or SERDs. Companies have spent hundreds of millions chasing a pill that could replace a monthly injection, only to watch pivotal trials crumble at the finish line. And yet, the field keeps pushing forward. Why? The answer lies in a compelling biological premise, an enormous unmet need, and a string of recent approvals that prove oral SERDs can, in fact, work. The story of SERDs is not a tale of failure; it&#8217;s a masterclass in scientific persistence.<\/p>\n\n\n\n<p>Hormone receptor-positive (HR+), <a href=\"https:\/\/www.delveinsight.com\/report-store\/her2-negative-breast-cancer-market\">HER2-negative breast cancer<\/a> represents the most prevalent subtype of breast cancer, accounting for approximately<strong> 70%<\/strong> of all diagnosed cases. In the 7MM, HR+\/HER2- breast cancer remains a key target indication for SERDs, with nearly <strong>481,000<\/strong> cases reported in 2024. The patient population is further anticipated to grow across the 7MM by 2036.<\/p>\n\n\n\n<p>These tumors depend on estrogen, specifically on the estrogen receptor (ER), to grow. For decades, the standard approach has been to starve the tumor of estrogen or block the receptor entirely, using drugs like tamoxifen or aromatase inhibitors (AIs). SERDs take a more aggressive stance: they don&#8217;t just block the estrogen receptor, they destroy it. By binding to ER and triggering its degradation, SERDs deprive cancer cells of a key survival signal entirely. The original SERD, <strong>fulvestrant (FASLODEX)<\/strong>, proved the concept could work, but it required monthly intramuscular injections, painful, inconvenient, and clinically suboptimal due to poor bioavailability.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-decade-of-heartbreak-the-failures-that-shaped-the-field\"><span class=\"ez-toc-section\" id=\"A_Decade_of_Heartbreak_The_Failures_That_Shaped_the_Field\"><\/span><strong>A Decade of Heartbreak: The Failures That Shaped the Field<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The path to an approved oral SERD is lined with broken pipelines. Understanding why so many promising drugs fell short is essential to understanding why the survivors matter so much. The most high-profile early collapse came from <strong>Sanofi<\/strong>. The French pharmaceutical giant&#8217;s <strong>amcenestrant<\/strong> was positioned as a potential blockbuster, with analysts eagerly watching the <strong>AMEERA-3 trial<\/strong>. When results finally arrived in 2022, delayed well beyond original projections, amcenestrant failed to beat physician&#8217;s choice therapy in progression-free survival (PFS). Sanofi&#8217;s stock fell, and the drug was placed on life support, with only early-line studies left to attempt a rescue.<\/p>\n\n\n\n<p>Meanwhile, a parade of early-stage candidates, <strong>GDC-029, AZD9496, GDC-0927, ZnC5, LSZ-102, brinalestrant (GDC-0810), and rintodestrant<\/strong>, were quietly shelved due to moderate efficacy in Phase 1 trials and an increasingly competitive landscape. The drug class that had promised so much was beginning to look like a dead end to some analysts.<\/p>\n\n\n\n<p>Most experts trace the failures to a combination of factors: suboptimal patient selection (not enriching for ESR1 mutations), testing in populations already heavily pre-treated, shorter drug half-lives reducing sustained receptor degradation, and the sheer difficulty of beating an already-moving standard of care that includes CDK4\/6 inhibitors like <strong>palbociclib, ribociclib, and abemaciclib<\/strong>.<\/p>\n\n\n\n<p><strong>Arvinas&#8217;s vepdegestrant<\/strong>, a <a href=\"https:\/\/www.delveinsight.com\/report-store\/protac-market-forecast\">PROTAC-based ER degrader<\/a>, technically a distinct mechanism, joined the list of partial disappointments in 2025 when it met only one of two co-primary endpoints in the VERITAC-2 trial, showing benefit only in the ESR1-mutant subgroup. Then, in March 2026, <strong>Roche <\/strong>delivered another blow: its oral SERD <strong>giredestrant <\/strong>failed to meet the primary endpoint of statistically significant PFS improvement in the persevERA trial, a first-line study combining giredestrant with palbociclib against letrozole plus palbociclib.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-survivors-in-the-graveyard\"><span class=\"ez-toc-section\" id=\"The_Survivors_in_the_Graveyard\"><\/span><strong>The Survivors in the Graveyard<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Despite the carnage, the class has proven it can work, when the right drug meets the right patient at the right moment. The key insight that changed everything: ESR1 mutations. <strong>Elacestrant&#8217;s (ORSERDU) <\/strong>approval in January 2023 was a watershed moment, making it the first oral SERD ever approved for breast cancer, a watershed moment for the field.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"245\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Timeline-of-SERDs-1024x245.webp\" alt=\"Timeline-of-SERDs\" class=\"wp-image-35390\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Timeline-of-SERDs-1024x245.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Timeline-of-SERDs-300x72.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Timeline-of-SERDs-150x36.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Timeline-of-SERDs-768x184.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Timeline-of-SERDs-1536x368.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Timeline-of-SERDs.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The approval was based on data from the landmark <strong>Phase 3 EMERALD trial<\/strong>, which enrolled patients with ER+\/HER2\u2212 advanced breast cancer who had progressed on one or two prior lines of endocrine therapy including a CDK4\/6 inhibitor. The results were striking: elacestrant reduced the risk of disease progression or death by 30% in the overall population and by 45% in patients with ESR1 mutations, offering a compelling, well-tolerated oral alternative to standard endocrine therapy.<\/p>\n\n\n\n<p>The approved indication targeted postmenopausal women and adult men with ER+, HER2\u2212, ESR1-mutated advanced or metastatic breast cancer after at least one prior line of endocrine therapy. For a patient population that had few good options post-CDK4\/6 inhibitor therapy, it was a genuine breakthrough. The momentum didn&#8217;t stop there. In September 2025, the FDA approved the second oral SERD: <strong>imlunestrant (INLURIYO)<\/strong> from <strong>Eli Lilly<\/strong>, for adults with ER+, HER2\u2212, <a href=\"https:\/\/www.delveinsight.com\/report-store\/esr1-mutated-metastatic-breast-cancer-market\">ESR1-mutated advanced or metastatic breast cancer<\/a> whose disease progressed following one or more prior lines of endocrine therapy.<\/p>\n\n\n\n<p>What sets imlunestrant apart is a unique feature among SERDs: it is brain-penetrant, capable of crossing the blood-brain barrier, a property that could make it effective against breast cancer that has metastasized to the brain. The approval was backed by the<strong> Phase 3 EMBER-3 trial<\/strong>, which showed that among patients with ESR1 mutations, half treated with imlunestrant monotherapy experienced at least 5.5 months of progression-free survival, compared to 3.8 months with standard therapy, a 38% reduction in the risk of progression. Additionally, imlunestrant was associated with longer median time to deterioration of quality of life (5.6 months vs. 3.8 months), a finding of immense importance for patients living with advanced disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-pipeline-brimming-with-promise\"><span class=\"ez-toc-section\" id=\"A_Pipeline_Brimming_with_Promise\"><\/span><strong>A Pipeline Brimming with Promise<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Two approved agents are just the beginning. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/serd-market-forecast\">oral SERD pipeline<\/a> is among the most active in oncology today, with multiple agents in late-stage development. <strong>Camizestrant<\/strong>, developed by <strong>AstraZeneca<\/strong>, has gained significant attention by showing antitumor efficacy in a range of preclinical models of breast cancer. The FDA recently notified AstraZeneca of an extension to the <strong>Prescription Drug User Fee Act (PDUFA) review<\/strong> timeline for the New Drug Application (NDA) of camizestrant combined with a CDK4\/6 inhibitor (palbociclib, ribociclib, or abemaciclib) as a first-line treatment for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer harboring emergent ESR1 mutations. The extension was requested to allow evaluation of additional supporting data.<\/p>\n\n\n\n<p>The NDA submission is supported by positive findings from the pivotal <strong>SERENA-6 Phase III trial<\/strong>, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine. In recognition of its potential clinical benefit, the FDA granted <strong>Breakthrough Therapy Designation<\/strong> to the camizestrant combination regimen in May 2025.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"436\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Emerging-SERD-in-Development-1024x436.webp\" alt=\"Emerging-SERD-in-Development\" class=\"wp-image-35393\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Emerging-SERD-in-Development-1024x436.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Emerging-SERD-in-Development-300x128.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Emerging-SERD-in-Development-150x64.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Emerging-SERD-in-Development-768x327.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Emerging-SERD-in-Development-1536x654.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Emerging-SERD-in-Development.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>However, in April 2026, the FDA\u2019s Oncologic Drugs Advisory Committee did not achieve a majority consensus supporting the clinical benefit of switching patients to camizestrant plus a <a href=\"https:\/\/www.delveinsight.com\/report-store\/cdk4-6-inhibitor-market-forecast\">CDK4\/6 inhibitor<\/a> based solely on ESR1 mutation detection in circulating tumor DNA before radiographic progression, as evaluated in the SERENA-6 trial.<\/p>\n\n\n\n<p>On the other hand, <strong>Giredestrant (Roche\/Genentech)<\/strong> is being evaluated in combination with targeted agents, including PI3K pathway inhibitors and everolimus, to explore synergistic strategies to overcome layered resistance mechanisms. Recently, in June 2026, the FDA accepted the New Drug Application (NDA) for giredestrant and granted it Priority Review status. A regulatory decision is anticipated by November 30, 2026.<\/p>\n\n\n\n<p><em>Sadaf Javed, an oncology expert at DelveInsight, said that if approved, giredestrant would become the first oral SERD for early-stage breast cancer, potentially displacing tamoxifen and aromatase inhibitors as the adjuvant standard of care for millions of patients globally.<\/em><\/p>\n\n\n\n<p>Meanwhile, next-generation agents like <strong>OP-1250 <\/strong>(Olema Oncology),<strong> SIM0270<\/strong> (Simcere), and <strong>AND019<\/strong> (Kind Pharmaceuticals) continue to advance through various trials, including in combination with CDK4\/6 inhibitors, with early data showing encouraging tolerability and anti-tumor activity even in heavily pre-treated populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-road-ahead-what-s-next-for-oral-serds\"><span class=\"ez-toc-section\" id=\"The_Road_Ahead_Whats_Next_for_Oral_SERDs\"><\/span><strong>The Road Ahead: What&#8217;s Next for Oral SERDs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The rise of oral SERDs represents one of the most significant advances in breast cancer treatment in the past decade. What began as the search for a more convenient alternative to a monthly injection has evolved into a sophisticated therapeutic revolution, one driven by a deeper understanding of estrogen receptor biology, resistance mechanisms, and the power of precision oncology.<\/p>\n\n\n\n<p>One emerging consensus across the field: oral SERDs alone may rarely be enough in heavily pre-treated patients. The future almost certainly lies in combination strategies, oral SERD paired with CDK4\/6 inhibitors, <a href=\"https:\/\/www.delveinsight.com\/report-store\/pi3k-market-forecast\">PI3K inhibitors<\/a>, or even other novel agents that target parallel resistance pathways.<\/p>\n\n\n\n<p>Elacestrant is already being evaluated in combination settings. Imlunestrant trials are exploring combinations with abemaciclib. Camizestrant&#8217;s SERENA-6 data showed its benefit layered on top of an existing CDK4\/6 inhibitor backbone. The irony is instructive: the same CDK4\/6 inhibitor combinations that oral SERDs must beat in the first-line setting are likely to become their closest partners in the second-line setting and beyond, working together to suppress multiple resistance mechanisms simultaneously.<\/p>\n\n\n\n<p>The field has not been without setbacks. High-profile failures like amcenestrant&#8217;s collapse across multiple trials are a reminder that biological promise does not automatically translate to clinical success. But the failures shaped the winners, teaching researchers exactly which patients benefit, which pharmacologic properties matter, and which trial designs can actually detect the signal.<\/p>\n\n\n\n<p>With two FDA-approved oral SERDs already in the clinic, a potential third (giredestrant), and combination and ctDNA-guided strategies continuing to evolve, the oral SERD story has reached an inflection point. The foundation has been laid. The next chapter is being written in real time.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/serd-market-forecast\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/SERD-Market-Outlook-1024x194.webp\" alt=\"SERD Market Outlook\" class=\"wp-image-35384\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/SERD-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/SERD-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/SERD-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/SERD-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/SERD-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/SERD-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary In the high-stakes world of breast cancer drug development, few drug classes have generated as much excitement, and as much heartbreak, as oral selective estrogen receptor degraders, or SERDs. Companies have spent hundreds of millions chasing a pill that could replace a monthly injection, only to watch pivotal trials crumble at the finish line. [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35382,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[127,22345,3879,23016,22414,23015],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-35380","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-breast-cancer","tag-cdk4-6-inhibitors","tag-metastatic-breast-cancer","tag-oral-serd","tag-protac","tag-serd","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Rise of Oral SERDs in Breast Cancer Treatment<\/title>\n<meta name=\"description\" content=\"The rise of oral SERDs represents one of the most significant advances in breast cancer treatment in the past decade.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Rise of Oral SERDs in Breast Cancer Treatment\" \/>\n<meta property=\"og:description\" content=\"The rise of oral SERDs represents one of the most significant advances in breast cancer treatment in the past decade.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-08T12:15:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T04:44:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/rise-of-oral-serds.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Rise of Oral SERDs in Breast Cancer Treatment","description":"The rise of oral SERDs represents one of the most significant advances in breast cancer treatment in the past decade.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds","og_locale":"en_US","og_type":"article","og_title":"The Rise of Oral SERDs in Breast Cancer Treatment","og_description":"The rise of oral SERDs represents one of the most significant advances in breast cancer treatment in the past decade.","og_url":"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-06-08T12:15:00+00:00","article_modified_time":"2026-06-09T04:44:36+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/rise-of-oral-serds.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds","url":"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds","name":"The Rise of Oral SERDs in Breast Cancer Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/rise-of-oral-serds.webp","datePublished":"2026-06-08T12:15:00+00:00","dateModified":"2026-06-09T04:44:36+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The rise of oral SERDs represents one of the most significant advances in breast cancer treatment in the past decade.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-oral-serds#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/rise-of-oral-serds.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/rise-of-oral-serds.webp","width":466,"height":284,"caption":"rise-of-oral-serds"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/rise-of-oral-serds-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CDK4\/6 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">metastatic breast cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oral SERD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PROTAC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">SERD<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">CDK4\/6 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">metastatic breast cancer<\/span>","<span class=\"advgb-post-tax-term\">Oral SERD<\/span>","<span class=\"advgb-post-tax-term\">PROTAC<\/span>","<span class=\"advgb-post-tax-term\">SERD<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 week ago","modified":"Updated 1 week ago"},"absolute_dates":{"created":"Posted on Jun 8, 2026","modified":"Updated on Jun 9, 2026"},"absolute_dates_time":{"created":"Posted on Jun 8, 2026 5:45 pm","modified":"Updated on Jun 9, 2026 10:14 am"},"featured_img_caption":"rise-of-oral-serds","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35380"}],"version-history":[{"count":6,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35380\/revisions"}],"predecessor-version":[{"id":35394,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35380\/revisions\/35394"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35382"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35380"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35380"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}